The team at Dana-Farber Brigham Cancer Center offers more clinical trials for breast cancer patients with brain metastases than any other center in the world. Our physicians and researchers are on the forefront of developing more effective treatments options for patients living
with brain metastases.
Should you participate in a clinical trial?
In recent years, clinical trials — some of which have been led at Dana-Farber Brigham Cancer Center — have led to many advances in the care and treatment of people with breast brain metastases. Today we have access to a range of options beyond radiation and surgery, including
targeted immunotherapy and systemic treatments.
Participating in a clinical trial is a very personal decision, and a choice that is completely yours to make. If it feels right to you, there are several good reasons to participate:
- Clinical trials are how we make progress against cancer.
- Taking part in a clinical trial can offer you new treatment options.
- By participating in a clinical trial, you contribute to knowledge that can help future patients.
Speak to your doctor about your clinical trial options. Learn more about clinical trials and whether participating in a clinical trial is right for you.
Research advances in breast cancer with brain metastases
In addition to providing expert care for patients with breast cancer, Dana-Farber Brigham Cancer Center physician scientists have been on the forefront of developing more effective treatments options for patients living with brain metastases for many
Dana-Farber Brigham Cancer Center investigators led the first clinical trials of HER2-targeted therapy for the treatment of breast cancer brain metastases. A combination of Lapatinib (Tykerb) with capecitabine (Xeloda) was the first targeted, systemic
treatment to demonstrate effectiveness in the brain in clinical trials. Dana-Farber Brigham Cancer Center investigators led the very first trials of this regimen, which is now included in national and international guidelines for treatment of HER2-positive
breast cancer that has spread to the brain.
The combination of Neratinib (Nerlynx) and capecitabine (Xeloda) can also be effective in the treatment of HER2-positive breast cancer brain metastases. Dana-Farber investigators led the trial leading to the inclusion of this treatment regimen in national
Dana-Farber Brigham Cancer Center physicians have led national and international efforts to improve the design of clinical trials for patients with breast cancer that has spread to the brain. Close collaborations between laboratory scientists and clinical
investigators has led to a series of exciting new clinical trials currently recruiting patients.
Current clinical trials
- Neratinib for Patients with HER2-Positive Breast Cancer with Brain Metastases
This study evaluates the response of the central nervous system to neratinib (Nerlynx®)-based treatments in patients with HER2-positive breast cancer
with brain metastases.
Video: Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain Metastases
- GDC-0084 with Trastuzumab in HER2-Positive Breast Cancer with Brain Metastases
This study evaluates the efficacy, safety, and tolerability of PI3K inhibitor GDC-0084 in combination with trastuzumab for the treatment of central
nervous system metastases in patients with HER2-positive metastatic breast cancer.
Video: Study of GDC-0084 with Trastuzumab in HER2-Positive Breast Cancer with Brain Metastases
- Atezolizumab with Pertuzumab and Trastuzumab in HER2-Positive Metastatic Breast Cancer
This study evaluates the efficacy, safety, and tolerability of atezolizumab in combination with pertuzumab and high-dose trastuzumab for the
treatment of central nervous system metastases in patients with HER2-positive metastatic breast cancer.
- Tesetaxel with Capecitabine vs Capecitabine Alone in HER2-Negative, HR-Positive, Locally Advanced or Metastatic Breast Cancer (CONTESSA)
This study compares the efficacy, safety, and tolerability of tesetaxel plus a reduced dose
of capecitabine versus the approved dose of capecitabine alone in patients with HER2-negative, HR-positive, locally advanced or metastatic breast cancer previously treated with a taxane.
- Atezolizumab with Stereotactic Radiation in Triple-Negative Breast Cancer with Brain Metastasis
This study evaluates the efficacy, safety, and tolerability of atezolizumab in combination with stereotactic radiation in patients
with triple-negative breast cancer with brain metastases.
- Whole-Brain Radiation vs. Stereotactic Radiation for Patients with 5-20 Brain Metastases
For most patients with greater than four brain metastases, whole brain radiation, in which the entirety of the brain is treated with radiation,
has historically been the standard treatment. Stereotactic radiation, in which a high dose of radiation is focused on the specific lesion(s) to be treated, with minimal dose to the surrounding brain, is an approach frequently used in patients
with one to four brain metastases. This study compares the efficacy of hippocampal-sparing whole brain radiation to stereotactic radiation in patients with 5-20 brain metastases and examines the quality of life of these patients following treatment.
Video: Study of Whole-Brain Radiation vs. Stereotactic Radiation for Patients with 5-20 Brain Metastases
- Screening MRI of the Brain in Metastatic Breast Cancer or Inflammatory Breast Cancer
This study aims to assess the impact of screening brain MRI on neurologic quality of life in patients with:
- NKTR-102 in Breast Cancer with Brain Metastases
This study compares the effects of topoisomerase I inhibitor polymer conjugate NKTR-102 with existing single-agent therapies. Physicians may select from the following list of seven
intravenous (IV) therapies: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
Ask your provider if any of these clinical trials may be right for you.
Search Dana-Farber Brigham Cancer Center clinical trials
Hugo Aerts, PhD
Ayal Aaron Aizer, MD, MHS
Omar Arnaout, MD
David Barbie, MD
Linda Bi, MD, PhD
Ugonma Chukwueke, MD
Rachel Freedman, MD, MPH
Alexandra Golby, MD
Daphne A. Haas-Kogan, MD
Raymond Y. Huang, MD, PhD
Sheheryar Kabraji, MB, ChB
Jose Pablo Leone, MD
Eudocia Quant Lee, MD
Keith Ligon, MD, PhD
Nancy U. Lin, MD
J. Ricardo McFaline-Figueroa, MD, PhD
Heather Parsons, MD, MPH
Pier Paolo Peruzzi, MD, PhD
Rifaquat Musaffa Rahman, MD
Sandro Santagata, MD, PhD
Timothy Smith, MD, PhD
Shyam Tanguturi, MD
Sara Tolaney, MD, MPH
Jean Zhao, PhD